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Outcomes of heart failure (HF) hospitalization are driven by the pres-
ence or absence of comorbid conditions. Cirrhosis is associated with
worse outcomes in patients with HF, and both HF and cirrhosis are
associated with worse renal outcomes. Using a nationally represen-
tative sample we describe inpatient outcomes of all-cause mortality
and length of stay (LOS) among patients with and without cirrhosis
hospitalized for decompensated with HF. We conducted a cross sec-
tional analysis using Nationwide Inpatient Sample (2010–2014) data
including patients hospitalized for decompensated HF, with or with-
out cirrhosis. We calculated the adjusted odds of all-cause mortality,
acute kidney injury (AKI), and target LOS after adjusting for poten-
tial confounders. Out of the 2,487,445 hospitalized for decompen-
sated HF 39,950 had cirrhosis of which majority (75.1%) were non-
alcoholic cirrhosis. Patients with comorbid cirrhosis were more likely
to die (OR, 1.26; 95% CI, 1.11 to 1.43) and develop AKI (OR, 1.26; 95% CI,
1.16 to 1.36) as compared to those without cirrhosis. Underlying CKD
was associated with a greater odds of AKI (OR, 4.99; 95% CI, 4.90 to
5.08), and the presence of cirrhosis amplified this risk (OR, 6.03; 95%
CI, 5.59 to 6.51). There was approximately a 40% decrease in the rela-
tive odds of lower HF hospitalization length of stay among those with
both CKD and cirrhosis, relative to those without either comorbidi-
ties. Cirrhosis in patients with hospitalizations for decompensated
HF is associated with higher odds of mortality, decreased likelihood
of discharge by the targeted LOS, and AKI. Among patients with HF
the presence of cirrhosis increases the risk of AKI, which in turn is as-
sociated with poor clinical outcomes.
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1. Introduction
Heart failure (HF) and liver cirrhosis as separate disease
entities contribute to significant morbidity and mortality in
the United States and worldwide [1, 2]. Cirrhosis may in-
fluence HF outcomes as it promotes a hyperdynamic state,
neurohormonal activation which can contribute to both sys-
tolic and diastolic myocardial dysfunction [3]. Furthermore,
both liver cirrhosis and HF can independently lead to poor
renal outcomes as reflected in the conditions of hepatorenal
syndrome (HRS) and cardiorenal syndrome (CRS) [3, 4]. In
hepatorenal syndrome, increased splanchnic blood flow with
decreased central volume accompanied by neurohormonal
activation leads to vasoconstriction decreasing renal blood
flow and glomerular filtration rate [5]. However, more re-
cently, this conventional liver-kidney or liver-heart crosstalk
has been challenged by emerging evidence accentuating the
role of the cardiac dysfunction as a potential mediator of re-
nal impairment in liver cirrhosis [3, 4]. Interactions between
the liver, heart, and kidney in the setting of CRS and HRS
share several cardinal mechanistic pathways [5, 6], but clini-
cal outcomes brought about by these interactions remain un-
derstudied.
We conducted a cross sectional analysis of nationally rep-
resentative sample of hospitalizations for decompensated HF
to assess the inpatient outcomes including all-causemortality,
acute kidney injury (AKI) and length of stay (LOS) duration
among those with relative to without comorbid cirrhosis.
2. Methods
We conducted a cross sectional analysis of the 2010
thru 2014 years of the National Inpatient Sample (NIS).
Briefly, the NIS of the Healthcare Cost and Utilization
Project (HCUP), sponsored by the Agency for Healthcare Re-
search andQuality (AHRQ), is a survey design-based database
of discharge data for inpatient care from non-federal (ex-
cludes Veterans Hospitals and other federal facilities), non-
rehabilitation, acute-care, short-term hospitals. The NIS is
an annual sample of hospital discharges that provides national
estimates of the characteristics of the patients, diagnoses, and
hospital-based procedures performed inUS acute-care hospi-
tals. Annually NIS includes approximately 7 million hospital
discharges. Detailed information on the NIS can be found on
its website (https://www.hcup-us.ahrq.gov/databases.jsp).
In our study sample of interest, hospitalizations for de-
compensated HF, was identified using the hospitalization
Diagnosis-Related Group (DRG) including 291, 292, and
293. Excluded were those aged younger than 18 years, and
those with hemodialysis (ICD 9: 39.95, V45.1, V56.0, V56.1)
or end stage renal disease (ICD-9: 585.6). HF subtype (dias-
tolic, systolic, and combined systolic and diastolic) and co-
morbid conditions including cirrhosis (alcoholic and non-
alcoholic), chronic kidney disease (CKD), cerebrovascular
disease, chronic obstructive pulmonary disease, hyperten-
sion, diabetes mellitus, and cancer were extracted using their
respective ICD-9 codes (see Supplemental Table 1). Target
LOS (tLOS) was defined as 2.8 days (d) for hospitalization as
determined by median time to discharge by Medicare level
DRG (DRG 293, 4.0 d for DRG 292, and 5.2 d for DRG of
291).
The study outcomes included all-cause inpatient mortal-
ity, acute kidney injury (AKI), and length of stay (LOS) dura-
tion shorter than the DRG-level Medicare tLOS.
Descriptive and inferential statistics was calculated while
incorporating the survey design features of the NIS data in
order to provide population-based estimates. Descriptive
statistics was calculated for categorical and continuous vari-
ables. Associations between categorical variables was deter-
mined using the design-adjusted Rao-Scott chi-square test.
Survey logistic regression provided the odds of study out-
come among thosewith related towithout cirrhosis adjusting
for age, gender, and additional comorbidities including CKD,
cerebrovascular disease, chronic obstructive pulmonary dis-
ease, hypertension, diabetes mellitus, and cancer. Unadjusted
and adjusted logistic regression by HF subtype provided the
odds of study outcome among those with relative to with-
out cirrhosis. A significance level of 0.05 with a 2-sided test
was used for all hypotheses. All statistical analyses were con-
ducted using SAS Statistical Software (SAS [9.4] Software,
SAS Institute Inc., Cary, NC, USA).
3. Results
3.1 Baseline characteristics
There were 2,487,445 hospitalizations for decompensated
HF in our study sample including 850,280 with diastolic,
1,358,235 with systolic, and 278,930 with combined HF.
The comorbid condition of cirrhosis was present among 39,
950 patients, which was predominantly of the non-alcoholic
type (75.1%) Systolic HF was the most prevalent subtype
in both those with or without cirrhosis (22,475 (56.3%) vs.
1,335,760 (53.7%)), followed by diastolic HF (13,050 (32.7%)
vs. 837,230 (33.7%)), and combined HF (4,425 (11.1%) vs.
274,505 (11.2%)). Table 1 displays characteristics of the HF
hospitalizations by cirrhosis status. Those with cirrhosis




n (%) or µ± SE n (%) or µ± SE
Age (y) <0.0001
18 to 40 775 (1.9) 51,825 (2.1)
40 to 65 17,815 (44.6) 583,355 (23.5)
65 and older 21,360 (53.5) 1,812,315 (72.9)
Female 14,520 (36.3) 1,238,950 (50.6) <0.0001
CKD 14,314 (35.8) 916,550 (37.4) 0.004
HTN 26,180 (65.5) 1,844,270 (75.4) <0.0001
DM 16,565 (41.5) 1,039,115 (42.5) 0.08
COPD 13,785 (34.5) 906,810 (37.1) <0.0001
Cancer 1,575 (3.9) 103,980 (4.2) 0.18
Charlson index 4.5± 0.02 3.2± 0.003 <0.0001
No. of chronic conditions 9.7± 0.04 8.6± 0.02 <0.0001
Abbreviations: n represents weighted frequency; %, percent; y, year; µ,
mean; SE, standard Error; CKD, Chronic Kidney Disease; CHF, congestive
heart failure; HTN, hypertension; DM, diabetesmellitus; COPD, chronic ob-
structive pulmonary disease.
were younger than those without cirrhosis (65.9 ± 0.2 vs.
73.2 ± 0.1 years (y); p < 0.0001). The average number of
coexisting conditions (9.7± 0.04 vs. 8.6± 0.02) and the av-
erage Charlson index score (4.5 ± 0.02 vs. 3.2 ± 0.003) was
higher among those with as compared to without cirrhosis.
Patients with coexisting cirrhosis were less likely to be female
(36.3% vs. 50.6%) or to have HTN (65.5% vs. 75.4%), CKD
(35.8% vs. 37.4%), or COPD (34.5% vs. 37.1%).
3.2 Outcomes: acute kidney injury
AKI occurred in 561,095 (22.56%) of the HF hospitaliza-
tions with a significantly higher occurrence of AKI among
those with as compared to without cirrhosis (26.49% vs.
22.49%; p < 0.0001). AKI occurred more commonly among
those with cirrhosis across all subtypes of HF including Dias-
tolic HF (3,330 (25.52%) vs. 198,075 (23.66%); p = 0.03), sys-
tolic HF (5,810 (25.85%) vs. 278,785 (20.87%); p < 0.0001),
and combined HF (1,430 (32.32%) vs. 73,665 (26.84%); p =
0.0002). Table 2 displays the adjusted odds of AKI among
HF hospitalizations with relative to without cirrhosis after
adjusting for confounding characteristics. After adjusting
for age, gender, and other comorbidities, HF hospitalizations
with cirrhosis had a greater risk of AKI relative to thosewith-
out (adjusted Odds Ratio (aOR), 1.23; 95% CI, 1.17 to 1.30).
Relative to those without either CKD or cirrhosis, those with
CKD without cirrhosis had a greater odds of AKI among HF
hospitalization (aOR, 4.99; 95%CI, 4.90 to 5.08), the presence
of concomitant CKD and cirrhosis amplified this heightened
risk (aOR, 6.03; 95% CI, 5.59 to 6.51) (see Table 3).
3.3 Outcomes: LOS
Over half of the HF hospitalizations (53.0%) had a LOS
below the tLOS. HF hospitalizations without cirrhosis were
more likely to have a LOS below tLOS (53.1% vs. 45.1%; p<
0.0001). By HF subtype, those without cirrhosis were more
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Table 2. Inpatient all-cause mortality, acute kidney injury,




Overall 1.23 (1.17, 1.30)
HF Sub Type
DSCHF 1.31 (1.13, 1.53)
SCHF 1.27 (1.16, 1.39)
DCHF 1.10 (1.00, 1.21)
Target length of stay
Overall 0.71 (0.68, 0.74)
HF Sub Type
DSCHF 0.70 (0.61, 0.81)
SCHF 0.66 (0.61, 0.71)
DCHF 0.75 (0.69, 0.81)
All-cause mortality
Overall 1.26 (1.11, 1.43)
HF Sub Type
DSCHF 1.58 (1.12, 2.22)
SCHF 1.20 (0.97, 1.49)
DCHF 1.10 (0.85, 1.43)
Abbreviations: OR represents Adjusted Odds Ratio;
CI, Confidence Interval; HF, Heart Failure; DSCHF,
combined systolic and diastolic congestive heart fail-
ure; SCHF, systolic congestive heart failure; DCHF,
diastolic congestive heart failure.
likely to have LOS below tLOS in the hospitalization for di-
astolic HF (53.1% vs. 45.6%; p < 0.0001), systolic HF (54.5%
vs. 45.6%; p < 0.0001), and combined HF (49.6% vs. 41.4%;
p < 0.0001). As displayed in Table 2, persons with relative
to those without cirrhosis had a 29% decrease in the relative
odds of having a LOS below tLOS (aOR, 0.71; 95% CI, 0.68
to 0.74). By HF subtype, persons with cirrhosis had the least
likely to have LOS below tLOS, as measured by % decrease
in relative odds, among systolic HF hospitalization (34%) fol-
lowed by combined HF (30%) and diastolic HF (25%) (see Ta-
ble 2). As shown in Table 3, HF hospitalizations with coex-
isting cirrhosis and CKD were least likely to have been dis-
charged by tLOS relative to thosewithout either cirrhosis and
CKD.
3.4 Outcomes: all-cause mortality
A total of 71,450 (2.9%) deaths among HF hospitalizations
with a higher mortality among patients with cirrhosis than
without cirrhosis (3.4% vs. 2.8%; p = 0.004). The higher
mortality among those with cirrhosis was noted among those
with systolic HF (3.7% vs. 3.2%; p = 0.03), and combined HF
(4.3% vs. 2.9%; p = 0.01) but not in the diastolic HF subtype
(2.5% vs. 2.4%; p = 0.55). After adjusting for confounders, HF
hospitalizations with comorbid cirrhosis had a higher risk of
mortality relative to those without cirrhosis (OR, 1.26; 95%
CI, 1.11 to 1.43). When assessed by HF subtype, the height-
ened risk of mortality with the coexistence of cirrhosis was
noted among those with combined HF (OR, 1.58, 95% CI,
Table 3. Impact of CKD and cirrhosis on the odds of target
length of stay and acute kidney injury among HF
hospitalizations.
tLOS AKI
aOR 95% CI aOR 95% CI
Overall
A Reference Reference
B 0.90 (0.89, 0.91) 4.99 (4.90, 5.08)
C 0.73 (0.69, 0.77) 1.26 (1.16, 1.36)




B 0.97 (0.93, 1.00) 4.34 (4.16, 4.34)
C 0.73 (0.61, 0.87) 1.46 (1.18, 1.81)
D 0.65 (0.52, 0.81) 5.14 (4.19, 6.31)
SCHF
A Reference Reference
B 0.91 (0.89, 0.92) 4.46 (4.35, 4.58)
C 0.68 (0.62, 0.75) 1.23 (1.08, 1.39)
D 0.56 (0.50, 0.64) 5.86 (5.19, 6.61)
DCHF
A Reference Reference
B 0.95 (0.93, 0.97) 5.00 (4.87, 5.14)
C 0.77 (0.69, 0.85) 1.15 (1.01, 1.32)
D 0.68 (0.60, 0.78) 5.25 (4.57, 6.03)
Abbreviations: aOR represents Adjusted Odds Ratio; tLOS, target
length of stay; AKI, acute kidney injury; CKD, chronic kidney dis-
ease; LOS, length of Stay; CI, Confidence Interval; A, no cirrhosis
or Chronic Kidney Disease; B, no cirrhosis but with Chronic Kidney
Disease; C, with cirrhosis but without CKD; D, with cirrhosis and
CKD.DSCHF, CombinedDiastolic and Systolic CHF; SCHF, Systolic
CHF; DCHF, Diastolic CHF; AdjustedModel adjusts for age, gender,
cerebrovascular disease, Chronic obstructive pulmonary disease, hy-
pertension, diabetes, cancer.
1.12 to 2.22) (See Table 2). Table 4 shows impact of AKI
and cirrhosis on the odds of all-cause mortality among HF
hospitalizations. As shown, those with coexisting cirrhosis
and who had AKI during the HF hospitalization had a greater
odds of mortality relative to those without either condition
(OR, 4.20; 95% CI, 3.55 to 4.97). This pattern of heightened
risk was noted across the HF subtypes.
4. Discussion
This analysis is, to the best of our knowledge, the
first observational report from a nationally representative
database on clinical outcomes in patients with hospitalized
HF with/without cirrhosis including AKI, mortality and im-
pact on hospital LOS. The presence of underlying cirrho-
sis increases mortality risk in patients with HF. A recent
analysis by Khalid et al. [7] showed an in-patient mortal-
ity rate of 3.4% among HF hospitalized patients with cir-
rhosis. Cirrhosis leads to a chronic hyperdynamic circula-
tory state coupled with low systemic vascular resistance, and
Volume 22, Number 3, 2021 927







B 2.97 (2.86, 3.09)
C 1.10 (0.91, 1.32)




B 3.14 (2.82, 3.51)
C 1.36 (0.78, 2.38)
D 5.29 (3.45, 8.11)
SCHF
A Reference
B 3.49 (3.27, 3.72)
C 1.08 (0.76, 1.52)
D 3.49 (3.27, 3.72)
DCHF
A Reference
B 3.22 (3.01, 3.46)
C 0.97 (0.64, 1.45)
D 3.99 (2.81, 5.69)
Abbreviations: OR represents Odds Ratio; CI, Confi-
dence Interval; A, no cirrhosis or Acute Kidney Injury;
B, no cirrhosis but with Acute Kidney Injury; C, with cir-
rhosis but without Acute Kidney Injury; D, with cirrhosis
and Acute Kidney Injury. DSCHF, Combined Diastolic
and Systolic CHF; SCHF, Systolic CHF; DCHF, Diastolic
CHF; Adjusted Model adjusts for age, gender, chronic
kidney disease, cerebrovascular disease, Chronic obstruc-
tive pulmonary disease, hypertension, diabetes, cancer.
provides a backdrop for independent cardiomyopathy from
the risk factors for the etiology of cirrhosis in itself (such
as NASH/amyloid/hemochromatosis) [8]. In the compen-
sated state, the hemodynamic derangements predominantly
in the form of arterial vasodilation are counterbalanced by
the augmentation of cardiac output [9]. However, in the
decompensated state, cardiac output may be inadequate to
compensate for the much more pronounced systemic vascu-
lar resistance reduction that eventually leads to central hy-
povolemia and arterial hypotension, feeding into vicious cy-
cle of sympathetic, renin-angiotensin-aldosterone, and va-
sopressin systems activation common to both cirrhosis as
well as HF [10]. Furthermore, due to hepatic dysfunction,
metabolism of drugs such as those used in HF may be im-
paired potentially limiting the use of guideline directed med-
ical therapy in this specific patient population that may affect
subsequent clinical outcomes [11]. This particular cohort of
patients with “hepato-cardiac” disease represent a potentially
high-risk group for poor outcomeswhen hospitalized for HF,
given the close crosstalk between HF and cirrhosis, with sev-
eral common aberrant, maladaptive pathways and possible
limitations to therapy.
Cirrhosis and HF are independent drivers of worsening
kidney function in their respective decompensated states vis
a vis hepatorenal syndrome (HRS) and cardiorenal syndrome
(CRS) respectively [4–6]. Interestingly, interactions between
these organs share cardinal mechanistic pathways including
neurohormonal activation and endothelial dysfunction [12].
In decompensated cirrhosis cardiomyopathy, the massive re-
nal vasoconstriction coupled with reduced cardiac output ad-
versely affects renal function [4, 13, 14]. A proof of concept
study in 2003 examined cardiac output during and after res-
olution of spontaneous bacterial peritonitis in cirrhotic pa-
tients [15]. Eight of the patients who developed HRS were
found to have lower cardiac output at baseline and declined
further at infection resolution, compared with the fifteen
who had normal function. This is the first clear evidence
that cardiac dysfunction may play a collateral pathogenic role
in HRS, with the use of the term “hepatocardiorenal syn-
drome” in the literature gaining recent traction [4]. Similarly,
congestive hepatopathy in the setting of decompensated HF
from elevated right atrial pressures adds the risk of further
decompensation of liver function, with secondary effects on
worsening kidney function [16–18]. Thus, the interplay of
“hepato-cardiac” disease in those with HF and underlying cir-
rhosis is potentially a major driver for poor kidney outcomes
as well as higher mortality and LOS with its attendant health
care resource utilization, as shown in this analysis.
In this analysis, the impact of underlying cirrhosis and the
development of worsening kidney function did not have a
differential effect in those with HFrEF vs HFpEF. This is of
clinical importance, as EF per se may not be the primary de-
terminant of outcomes with the maladaptive “hepato-cardio-
renal-axis” [4]. In fact, LV systolic dysfunction may be latent
in cirrhosis, and may require provocative testing to identify
the presence of cardiomyopathy [19]. Thus, the mere preser-
vation of EF should not be a deterrent to a more nuanced
approach to diagnosing cardiomyopathy in patients with cir-
rhosis, especially with the consideration to be able to mod-
ify the disease trajectory with appropriate guideline directed
medical therapies for HF early in the course, given the high
burden of mortality and resource utilization in the decom-
pensated state, as shown in this cross-sectional analysis.
5. Limitations
Our study has several limitations. The use of an adminis-
trative dataset and the cross-sectional nature of our study de-
sign limit the ability to capture patient level data. Other limi-
tations include the lack of information in the database regard-
ing the severity of the conditions described lack of an indica-
tor for whether a condition was present on admission or not,
and non-availability a disease state relevant to the outcome
of interest, and potential residual confounding. Also, we re-
lied on hospitalization DRG to identify the main indication
928 Volume 22, Number 3, 2021
for the hospitalization to have been for HF which allows for
administrative error. We were not able to look at the influ-
ence of potential suboptimal use of guideline directedmedical
therapy given the more complex hemodynamic nature of the
interplay of cirrhosis and heart failure with potentially lower
blood pressure ranges. Nevertheless, these results describe
the high burden of poor outcomes in patients with “cardio-
hepatic” disease and its attendant costs on the health system,
and are hypothesis generating towards design of future stud-
ies to alter the trajectory of this axis with the recognition of
high-risk phenotypes and institution of appropriate guideline
based medical therapies.
6. Conclusions
Patients hospitalized with HF and underlying cirrhosis
may be at higher risk for poorer clinical outcomes. Prospec-
tive studieswith control for potential confoundersmay better
delineate this association.
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